
IHRæ¹æ£æ¡ã®è泚ã«è¿œå ããããWHOã®äºåèªèšŒããšã¯ïŒ
2024幎 4æ22æ¥ïœ26æ¥ã IHRæ¹æ£ã®äœæ¥éšäŒïŒç¬¬8å WGIHR / 8ïŒãè¡ãããŠããŸããSNSã§ãæ¹æ£æ¡ã«é¢ããæ
å ±ãåºå§ããããæ¹åã«å€ãã£ããšããèŠè§£ãåºãŠããããã§ããããŸã æçµæ±ºå®ã§ã¯ãããŸãããWHOã®ã¹ããŒã¯ãã«ããŒã§ãããThird World Networkãã®ãµã€ãã«ãã第8åWGIHRäŒè°ã§è°è«ãããŠããå
容ã«é¢ããèšäºããããŸããããããå
ã«æãèµ·ãããè³æããèŠããŠãããWHOã®äºåèªèšŒã«ã€ããŠåãäžããŸãã
IHRæ¹æ£äœæ¥éšäŒã®è³æ
ã¹ããŒã¯ãã«ããŒã«ã€ããŠã¯ãäžèšã®èšäºã§åãäžããŸããã
é¢é£å©å®³é¢ä¿è
ã®ãªã¹ã
Modalities of engagement for relevant stakeholders
ãThird World Networkãã¯ã
Annex E: Other stakeholders, as decided by the INB, invited to provide inputs to the INB (via anelectronic portal, an open âhearingâ, and/or a segment of a session)ã®95ã«ãããŸãã
éå ¬éã®äŒè°ã«ã¯åå ã§ããªãããã§ãããè°è«ã®å 容ãç¥ãããšãã§ããæèŠãèšããç«å Žãšããããšã ãšæããŸãã

2024幎4æ22æ¥ã®èšäºãã
å€ãã®ããšãæžãããŠããŠé ãã¯ã©ã¯ã©ããŠããŸãããç§ãæ°ã«ãªã£ãã®ã¯äžèšã®éšåã§ãã
Moreover, a proposal of the Bureau to add a footnote to Annex 6 (on vaccination, prophylaxis and related certificates) effectively neutralises equitable access especially through local production. Paragraph 3 of Annex 6 states âCertificates under this Annex are valid only if the vaccine or prophylaxis used has been approved by WHOâ. The proposed footnote to this Para now states:
âApproved by WHO refers to health products evaluated and listed by WHO under the WHO Prequalification (PQ) procedures, applicable to medicines, vaccines, in-vitro diagnostics, vector control products, immunisation devices; and inspection services; and Emergence Use Listing (EUL) procedures, applicable to medicines, vaccines, in-vitro diagnosticsâ.
A similar footnote is also proposed to the model international vaccination and prophylaxis certificate, which is part of Annex 6. This means that vaccination, prophylaxis or related certificate under the IHR will be recognised for international travel and related purpose only when the product used is prequalified by WHO.
éé²ç¬¬ 6 (äºé²æ¥çš®ãäºé²è¬åã³é¢é£èšŒææž)ã®éšåã«ãèæ³šã远å ãããšããäºåå±ã®ææ¡ããã£ããšæžãããŠããŸãã
ããã«ãåæ§ã®è泚ããéé²ç¬¬ 6 ã®äžéšã§ãããäºé²æ¥çš®åã¯äºé²è¬ã«é¢ããåœéèšŒææžã®æ§åŒãéšåã«ããããšæžãããŠããŸãã
WHOã®ãµã€ãã§å ¬éãããŠããåæã確èªããŸããã
56ããŒãžãAnnex 6

3ã®æåŸã«ããWHOã«1ãšããŠãäžèšã®è泚ã远å ãããŠããã®ã§ãã

59ããŒãžã«ããäžèšã®æç« ãããåãèæ³šã远å ãããŠããŸãã

æ¬èšŒææžã¯ãæ¥çš®ãããã¯ã¯ãã³åã¯äºé²è¬ãäžçä¿å¥æ©é¢ã«ãã£ãŠæ¿èªããããã®ã§ããå Žåã«ã®ã¿æå¹ã§ããã

èæ³šã«ã¯ããWHOã«ãã£ãŠæ¿èªãããããšã¯ãWHO äºåèªèšŒ (PQ) ã®æé ã«åºã¥ããŠWHO ã«ãã£ãŠè©äŸ¡ããã³ãªã¹ãåããã補åãæããšãããŸãã
ååŽçãå ¬éããŠããæ¹æ£åã®ä»®èš³ãèŠããšã確ãã«è泚ã¯ãããŸããã
éé²ïŒä»®èš³ïŒ(PDF)


ãã®ãWHOã®äºåèªèšŒ(PQ)ãã¯ä»¥åãäžèšã®èšäºã§åãäžããŸããããæ¥æ¬ãããããã¯ã¯ãã³ã茞åºããããã«ã¯PQãäžå¯æ¬ ã ãšããè³æã倿°ãããŸããã
WHOã®äºåèªèšŒïŒPQïŒ
PQã®æé ã«ã€ããŠã¯ãäžèšã®ããŒãžã«æžãããŠããŸãã
ç³è«ãããšãWHO ã¹ã¿ãããšååœèŠå¶åœå±ã®å°éå®¶ã«ãã£ãŠè©äŸ¡ãããããã§ããç³è«è²»çšã«ã€ããŠèª¿ã¹ãŠã¿ãããããªãé«é¡ïŒ
ç³è«è²»çšã®ã»ããèªèšŒãããåŸãèªèšŒã®ã¹ããŒã¿ã¹ãç¶æããããã«å¹Žéç¶æè²»ããããããã§ããäžåºŠèªèšŒãããã®ã«å¯ŸããŠããªãç¶æè²»ãå¿ èŠãªã®ã§ããããããŸãã§æªè³ªãªè³æ Œåæ³ã®æå£ã§ãã


äžèšã¯äžè±UFJãªãµãŒãïŒã³ã³ãµã«ãã£ã³ã°ã«ããè³æïŒ2017幎ïŒã§ããããããšæ¯ã¹ããšããªãå€äžããããŠããããšãããããŸãã
ãWHO PrequalificationæŠèŠã«é¢ããèªäž»èª¿æ»å ±åã
2017幎3æ14æ¥

ãã®ãããªã·ã¹ãã ã§ã¯ãç³è«è²»çšã®åºããªãåœã¯ãèªåœã§äœã£ãã¯ã¯ãã³ãWHOã«äºåèªèšŒããŠãããããšã¯ã§ããªãã§ãããããããªãã°ãçµå±ãWHOãæ±ºããããã«ã¯ã¯ãã³æ¥çš®ãé²ããããŠããŸããŸããWHOã«ç³è«è²»çšãæ¯æããåœã®ãWHOã®ã¹ããŒã¯ãã«ããŒã«ãªã£ãŠããå£äœã«å çããŠãã補è¬äŒç€Ÿã®ãWHOã«äºåèªèšŒãããã¯ã¯ãã³ããæ¿èªãããã¯ã¯ãã³ããšãããããšã«ãªãã®ã§ã¯ãªãã§ããããã
éäžåœã¯ãã¯ã¯ãã³ãžã®ãå ¬å¹³ãªã¢ã¯ã»ã¹ããæ±ããŠIHRæ¹æ£ããã³ãããã¯æ¡çŽ(仮称)ã®äº€æžãç¶ããŠããŸããããã®ãããªããæ¹ã§ãå ¬å¹³ãªã¢ã¯ã»ã¹ããå®çŸã§ãããšã¯æããŸãããã¯ã¯ãã³ã®åé ã«ã€ããŠã®çŽæããä»ã®èæ¡ïŒãã³ãããã¯æ¡çŽïŒã«ã¯æžãããŠããªãã®ã§ãããŠããããã§ãã
ãããããéäžåœããå¿ èŠãªã¯ã¯ãã³ã¯å ¬å¹³ã«åé ããŠïŒããšèŠæ±ããŠããã®ã¯ãWHOãmRNAã¯ã¯ãã³ã®åã£ãæ å ±ã°ãããäŒããŠãããããªã®ã§ãããããåŒ·å¶æ¥çš®ã«ãªãã®ã§ã¯ãšããäžå®ãæããŠããç§ãã¡ãšã¯ãéãªã®ãäžæè°ã§ãã
WHOã®äºåèªèšŒã«é¢ããŠãæ¥æ¬ã¯è£å©éãŸã§åºããŠããŸããè³æ Œåæ³ã®ããã«ã¢ã«ãããŠãããšããæããŸãããã
WHOã¯ãPQã§åŸããéãã©ãã«äœ¿ã£ãŠããã®ã§ããããã
宿¿é·å®ã®çºèš
å æ¥ã®äŒèŠã§æå®æ¿é·å®ã¯ãã¯ã¯ãã³ãšã¯ã¯ãã³ãã¹ããŒãã«ã€ããŠè³ªåãããã®ã«ãã¯ã¯ãã³ãã¹ããŒãã«ã€ããŠã¯çããŸããã§ããïŒäžèšåç §ïŒã
äŒèŠã§ã¯ããæãåœã«ãããŠã¯ãäºé²æ¥çš®ã¯å¯Ÿè±¡è ãŸãã¯ãã®ä¿è·è ããããåãããåŠãã倿ãããã®ã§ãããŸããŠãæ¥çš®ã匷å¶ããããã®ã§ã¯ãªããšããããšã§ããããŸãããšèšã£ãŠããŸãããããã©ãã匷å¶ã§ãªããŠããWHOãäºåèªèšŒããã¯ã¯ãã³ãæ¥çš®ããŠããªããšè¡åãå¶éãããå¯èœæ§ã¯ããã®ã§ã¯ãªãã§ããããã
ããã¯æšæž¬ã§ããã匷å¶ã§ã¯ãªã圢ã§ã¯ã¯ãã³æ¥çš®ãããããåŸãªãç¶æ³ãäœãããå¯èœæ§ãããããã宿¿é·å®ã¯ã¯ã¯ãã³ãã¹ããŒãã«ã€ããŠã¯çããªãã£ãã®ã§ã¯ãªãã§ããããã
IHRæ¹æ£ããã³ãããã¯æ¡çŽã«é¢ããè³æã¯å°éçšèªãªã©ãå€ããŠé£ããã®ã§ãèªãã§ããã ãã§ã¯ã©ã¯ã©ããŠããŠããŸããŸãã翻蚳ãµã€ãã䜿ã£ãŠãããŸãããã©ãèšãæ¹ãããŠãããããã®ã§ãããããããªãéšåãå€ãã§ããå°éçãªããšã¯ããããªãã®ã§ãééãããããããããŸããããèªåã調ã¹ãããšã誰ãã®åœ¹ã«ç«ã€ãããããªãã®ã§èšäºã«ãŸãšããŸããã
èªåãå®¶æã®èº«ãå®ãããã«ã¯ãããšãããããšãããå°ããããªãã£ããšããŠããèªåã§ç¢ºèªããããšããããšã倧åã ãšæããŸãããã®ãå°ããã®äžãããéèŠãªããšãèŠããŠãããããããŸãããèŠããŠããããšãšãä»ã®äººã®èããã€ãªãåãããããå€ãã®ããšãèŠããŠããã¯ãã§ãïŒ